Positron emission tomography/magnetic resonance imaging with68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?
Open Access
- 21 July 2014
- journal article
- case report
- Published by Wiley in International Journal of Urology
- Vol. 21 (12) , 1286-1288
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Hybrid Positron Emission Tomography–Magnetic Resonance Imaging with Gallium 68 Prostate-specific Membrane Antigen Tracer: A Next Step for Imaging of Recurrent Prostate Cancer—Preliminary ResultsEuropean Urology, 2013
- Critical Evaluation of Magnetic Resonance Imaging Targeted, Transrectal Ultrasound Guided Transperineal Fusion Biopsy for Detection of Prostate CancerJournal of Urology, 2013
- The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2013
- Sensitivity of PET/MRI to detect recurrence of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancerEJNMMI Research, 2012
- First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic DiagnosesJournal of Nuclear Medicine, 2012
- [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECHEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012